J. Llibre

发表

Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection

U. Spengler, J. Trebicka, J. Rockstroh, 2019, HIV medicine.

Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. Hepatitis/HIV Spanish Study Group.

J. Castilla, J. García-Samaniego, V. Soriano, 1997, AIDS.

Nucleoside reverse transcriptase inhibitor‐reducing strategies in HIV treatment: assessing the evidence

A. Antinori, C. Orkin, S. Gallien, 2018, HIV medicine.

Global HIV‐1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

J. Lundgren, D. Dunn, A. Geretti, 2015, HIV medicine.

Hospital outbreak of scabies stemming from two AIDS patients with Norwegian scabies

B. Clotet, J. Romeu, G. Sirera, 1990, The Lancet.

Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study

A. Curran, E. Pedrol, O. Martínez-Madrid, 2015, HIV medicine.

Transient Treatment Exclusively Containing Nucleoside Analogue Reverse Transcriptase Inhibitors in Highly Antiretroviral-Experienced Patients Preserves Viral Benefit When a Fully Active Therapy Was Initiated

J. Martinez-Picado, E. Negredo, S. Videla, 2008, HIV clinical trials.

Unplanned antiretroviral treatment interruptions, genetic barrier, and development of resistance

B. Young, J. Llibre, 2014, HIV medicine.

Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV‐1‐infected patients with multidrug‐resistant virus: a multicentre pilot study

J. Schapiro, J. Martinez-Picado, E. Negredo, 2008, HIV medicine.

Host and disease factors are associated with cognitive function in European HIV‐infected adults prior to initiation of antiretroviral therapy

H. Amièva, A. Winston, A. Antinori, 2016, HIV medicine.

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

T. Harrer, A. Winston, E. Harrer, 2023, Scientific Reports.

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single‐tablet regimen in the expanding spectrum of fixed‐dose combination therapy for HIV

H. Stellbrink, A. Lazzarin, I. Woolley, 2020, HIV medicine.

Hill A, Moyle G. Relative antiviral efficacy of ritonavir‐boosted darunavir and ritonavir‐boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259–264

J. Llibre, Núria Pérez-Álvarez, 2007, HIV medicine.